• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.82% Nasdaq Up0.41%

    GTX Inc. (GTXI)

    0.96 Down 0.01(1.02%) Oct 8, 3:57PM EDT
    ProfileGet Profile for:
    GTX Inc.
    175 Toyota Plaza
    7th Floor
    Memphis, TN 38103
    United States - Map
    Phone: 901-523-9700
    Fax: 901-844-8075
    Website: http://www.gtxinc.com

    Index Membership:N/A
    Full Time Employees:28

    Business Summary 

    GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules for the treatment of cancer and other serious medical conditions. Its lead product candidate, enobosarm (GTx-024), is in Phase 2 clinical trials for the treatment of women with advanced AR positive triple-negative breast cancer, and treatment of women with ER positive and AR positive advanced breast cancer. The company also develops Capesaris, an oral nonsteroidal estrogen receptor alpha agonist that is in Phase 2 clinical trial for secondary hormonal therapy in men with metastatic or nonmetastatic castration resistant prostate cancer. GTx, Inc. was founded in 1997 and is headquartered in Memphis, Tennessee.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on GTX Inc.

    Corporate Governance 
    GTX Inc.’s ISS Governance QuickScore as of Jul 1, 2014 is 10. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 8; Compensation: 10.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. Marc S. Hanover MBA, 52
    Co-founder, Chief Exec. Officer and Director
    Mr. Jason T. Shackelford , 40
    Principal Financial & Accounting Officer, Sr. Director of Accounting and Corp. Controller
    Mr. Henry P. Doggrell , 66
    Chief Legal Officer, VP, Gen. Counsel and Sec.
    Dr. Robert James Wills Ph.D., 61
    Exec. Chairman and Chairman of Scientific & Devel. Committee
    Mr. Michael Denny Brown ,
    VP of Marketing and Managed Care
    Dr. Diane Young M.D.,
    Chief Medical Officer and VP
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders